ATE395049T1 - Verbesserte pharmazeutische zusammensetzungen von hiv-proteasehemmern - Google Patents

Verbesserte pharmazeutische zusammensetzungen von hiv-proteasehemmern

Info

Publication number
ATE395049T1
ATE395049T1 AT00982360T AT00982360T ATE395049T1 AT E395049 T1 ATE395049 T1 AT E395049T1 AT 00982360 T AT00982360 T AT 00982360T AT 00982360 T AT00982360 T AT 00982360T AT E395049 T1 ATE395049 T1 AT E395049T1
Authority
AT
Austria
Prior art keywords
pharmaceutical compositions
hiv protease
protease inhibitors
improved pharmaceutical
improved
Prior art date
Application number
AT00982360T
Other languages
English (en)
Inventor
Laman Alani
Soumojeet Ghosh
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23936923&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE395049(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Application granted granted Critical
Publication of ATE395049T1 publication Critical patent/ATE395049T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
AT00982360T 2000-01-19 2000-12-01 Verbesserte pharmazeutische zusammensetzungen von hiv-proteasehemmern ATE395049T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US48773900A 2000-01-19 2000-01-19

Publications (1)

Publication Number Publication Date
ATE395049T1 true ATE395049T1 (de) 2008-05-15

Family

ID=23936923

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00982360T ATE395049T1 (de) 2000-01-19 2000-12-01 Verbesserte pharmazeutische zusammensetzungen von hiv-proteasehemmern

Country Status (26)

Country Link
EP (3) EP1917958B1 (de)
JP (1) JP4769400B2 (de)
KR (1) KR100861885B1 (de)
CN (1) CN100536833C (de)
AT (1) ATE395049T1 (de)
AU (2) AU1940501A (de)
BG (1) BG66112B1 (de)
BR (1) BR0011864A (de)
CA (1) CA2395987C (de)
CY (3) CY1108197T1 (de)
CZ (1) CZ304118B6 (de)
DE (1) DE60038899D1 (de)
DK (3) DK1248600T3 (de)
ES (3) ES2304990T3 (de)
HK (1) HK1120213A1 (de)
HU (1) HU229778B1 (de)
IL (2) IL150265A0 (de)
MX (1) MXPA02007097A (de)
NO (1) NO331400B1 (de)
NZ (1) NZ519724A (de)
PT (3) PT1248600E (de)
SI (3) SI1248600T1 (de)
SK (1) SK287143B6 (de)
TR (1) TR201809435T4 (de)
WO (1) WO2001052821A1 (de)
ZA (1) ZA200205109B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1175205B1 (de) 1999-11-12 2006-06-14 Abbott Laboratories Feste dispersion mit ritonavir, fenofibrat oder griseofulvin
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
GB0615211D0 (en) * 2006-07-31 2006-09-06 Ge Healthcare Uk Ltd Asymmetric flouro-substituted polymethine dyes
EP2188265A1 (de) * 2007-08-07 2010-05-26 Ranbaxy Laboratories Limited Verfahren zur herstellung von amorphem lopinavir
CA2837266A1 (en) 2011-05-27 2012-12-06 Hetero Research Foundation Amorphous ritonavir co-precipitated
GB201808564D0 (en) 2018-05-24 2018-07-11 Douglas Pharmaceuticals Ltd Treatments

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US594836A (en) * 1897-11-30 Corner-brace
US5354866A (en) 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
US5539122A (en) 1989-05-23 1996-07-23 Abbott Laboratories Retroviral protease inhibiting compounds
GB8927913D0 (en) 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
JPH06505963A (ja) 1990-11-19 1994-07-07 モンサント　カンパニー レトロウイルスプロテアーゼ阻害剤
CA2056911C (en) 1990-12-11 1998-09-22 Yuuichi Nagano Hiv protease inhibitors
EP0532466A3 (en) 1991-09-12 1993-06-16 Ciba-Geigy Ag Derivatives of 5-amino-4-hydroxy-hexanoic acid and their therapeutical use
DE69232568T2 (de) 1991-10-11 2002-12-19 Bristol Myers Squibb Pharma Co Cyclische Harnstoffe und Analoga verwendbar als retrovirale Proteasehemmer
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
CA2081970C (en) 1991-11-08 1997-07-08 Joseph P. Vacca Hiv protease inhibitors useful for the treatment of aids
EP0560268B1 (de) 1992-03-13 1995-01-04 Bio-Mega/Boehringer Ingelheim Research Inc. Substituierte Pipecoline-Säurederivate als HIV-Protease-Hemmer
AU676479B2 (en) 1992-05-20 1997-03-13 G.D. Searle & Co. Method for making intermediates useful in synthesis of retroviral protease inhibitors
US5559256A (en) 1992-07-20 1996-09-24 E. R. Squibb & Sons, Inc. Aminediol protease inhibitors
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US5484926A (en) 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
ES2317977T3 (es) 1992-12-29 2009-05-01 Abbott Laboratories Procedimientos e intermediarios para la preparacion de inhibidores de proteasa retrovirales.
WO1995006061A1 (en) 1993-08-20 1995-03-02 G.D. Searle & Co. Retroviral protease inhibitors and combinations thereof
IL110752A (en) 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en) 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
US5491253A (en) 1993-10-22 1996-02-13 Abbott Laboratories Process for the preparation of a substituted 2,5-diamino-3-hydroxyhexane
IL111991A (en) 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
IL129871A (en) 1994-05-06 2003-11-23 Pharmacia & Upjohn Inc Process for preparing 4-phenyl-substituted octanoyl-oxazolidin-2-one intermediates that are useful for preparing pyran-2-ones useful for treating retroviral infections
US5567823A (en) 1995-06-06 1996-10-22 Abbott Laboratories Process for the preparation of an HIV protease inhibiting compound
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
JP2000502997A (ja) * 1995-12-13 2000-03-14 アボツト・ラボラトリーズ レトロウイルスプロテアーゼ抑制化合物
US6160122A (en) 1996-06-28 2000-12-12 Abbott Laboratories Process for the preparation of a disubstituted thiazole
ZA9710071B (en) * 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.
CA2371109C (en) * 1999-06-04 2011-04-26 Laman A. Alani Improved pharmaceutical formulations

Also Published As

Publication number Publication date
AU2006235895B2 (en) 2009-08-13
EP1917958B1 (de) 2012-06-13
CZ304118B6 (cs) 2013-11-06
NO20023455L (no) 2002-09-18
HUP0302070A2 (hu) 2003-09-29
IL150265A0 (en) 2002-12-01
SK287143B6 (sk) 2010-01-07
EP2269591B1 (de) 2018-04-04
CY1120408T1 (el) 2019-07-10
JP4769400B2 (ja) 2011-09-07
SI1917958T1 (sl) 2012-10-30
SI2269591T1 (en) 2018-08-31
BG66112B1 (bg) 2011-05-31
CN100536833C (zh) 2009-09-09
HU229778B1 (hu) 2014-07-28
DK1248600T3 (da) 2008-09-08
ES2676151T3 (es) 2018-07-17
PT1917958E (pt) 2012-08-16
CZ20022663A3 (cs) 2002-11-13
BR0011864A (pt) 2004-07-20
PT1248600E (pt) 2008-08-25
EP1248600A1 (de) 2002-10-16
DK2269591T3 (en) 2018-07-16
AU2006235895A1 (en) 2006-11-30
PT2269591T (pt) 2018-07-09
CY1108197T1 (el) 2014-02-12
JP2003533435A (ja) 2003-11-11
CA2395987C (en) 2009-12-22
KR20020082210A (ko) 2002-10-30
IL150265A (en) 2015-02-26
EP1917958A3 (de) 2008-08-27
HK1120213A1 (en) 2009-03-27
ZA200205109B (en) 2003-10-31
SI1248600T1 (sl) 2008-08-31
AU1940501A (en) 2001-07-31
NO331400B1 (no) 2011-12-19
EP2269591A3 (de) 2011-07-27
ES2387579T3 (es) 2012-09-26
NO20023455D0 (no) 2002-07-18
TR201809435T4 (tr) 2018-07-23
ES2304990T3 (es) 2008-11-01
EP1917958A2 (de) 2008-05-07
BG106976A (bg) 2003-05-30
KR100861885B1 (ko) 2008-10-09
HUP0302070A3 (en) 2007-02-28
MXPA02007097A (es) 2003-01-28
EP2269591A2 (de) 2011-01-05
CA2395987A1 (en) 2001-07-26
NZ519724A (en) 2004-07-30
EP1248600B1 (de) 2008-05-14
DE60038899D1 (de) 2008-06-26
CN1424907A (zh) 2003-06-18
PL361396A1 (en) 2004-10-04
DK1917958T3 (da) 2012-09-24
CY1112995T1 (el) 2016-04-13
WO2001052821A1 (en) 2001-07-26
SK11102002A3 (sk) 2002-12-03

Similar Documents

Publication Publication Date Title
CY1105237T1 (el) Βελτιωμεναι φαρμακευτικαι διαμορφωσεις πepιλαμβανουσαι ritonavir
ATE516017T1 (de) Feste pharmazeutische dosierform enthaltende ritonavir
CY1120408T1 (el) Βελτιωμενες φαρμακοτεχνικες μορφες
TR200103493T2 (tr) Metaloproteaz önleyicileri
MXPA03006224A (es) Inhibidores de cruzipaina y otras proteasas de cisteina.
NO20031909L (no) Selvemulgerende, orale doseringsformuleringer av pyranon protease-inhibitorer
SE0001916D0 (sv) Novel formulation
WO2002057246A3 (en) Inhibitors of cruzipain and other cysteine proteases
UY27033A1 (es) Nuevos compuestos para su uso como inhibidores de la proteasa de vih
IT1318654B1 (it) Composizioni farmaceutiche comprendenti agenti antiinfiammatori e lorousi.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1248600

Country of ref document: EP